Recommended Topic Related To:

Dynacirc CR

"Dec. 18, 2012 -- People who can't get their high blood pressure down with drugs may be helped by a new procedure that deactivates overactive nerves in the kidneys, a small study shows.

The procedure is already available in Europe and "...

Dynacirc CR

SIDE EFFECTS

In a controlled clinical trial with DynaCirc CR® (isradipine), dose-related edema occurred at an incidence of approximately 9% at 5 mg; 13% at 10 mg; 16% at 15 mg; and 36% at the highest dose studied (20 mg), was mild to moderate in severity,and was not related to age or gender.

The incidences of elicited or volunteered adverse reactions (excluding non-drug related) in the following tables are based on 6-week multicenter, placebo-controlled, double-blind hypertension studies. Less than 1% of DynaCirc CR® (isradipine) or placebo-treated patients discontinued from these studies due to adverse reactions.

The most common adverse experiences ( ≥ 1.0%) reported with DynaCirc CR® (isradipine) in a dose-response study are shown in the following table.There were no discontinuations of patients treated with DynaCirc CR® (isradipine) in this study due to these common side effects.

Most Frequently Reported Newly-Occurring Adverse Reactions in Dose-Response Study

Adverse Reactions (Excluding Non-Drug Related) DynaCirc CR® (isradipine)
5 mg
(N=79)
10 mg
(N=79)
15 mg
(N=82)
20 mg
(N=78)
Placebo Group
(N=83)
Headache 13.9% 12.7% 18.3% 10.3% 15.7%
Edema 8.9% 12.7% 15.9% 35.9% 3.6%
Dizziness 5.1% 6.3% 3.7% 6.4% 2.4%
Constipation 3.8% 1.3% 1.2% 2.6% 0.0%
Fatigue 2.5% 7.6% 3.7% 3.8% 2.4%
Flushing 2.5% 3.8% 1.2% 1.3% 1.2%
Abdominal Discomfort 1.3% 5.1% 3.7% 5.1% 1.2%
Rash 1.3% 1.3% 0.0% 2.6% 0.0%

The table below shows elicited or volunteered adverse experiences for DynaCirc CR® (isradipine) treated patients in two 6-week, placebo-controlled, multicenter studies, at doses from 5-20 mg, and considered by the investigator to be at least possibly drug related.The results for DynaCirc CR® (isradipine) treated patients are presented for all doses pooled together (reported by at least 1.0% of active drug treated patients).The incidence of adverse reactions are listed below:

Adverse Reactions (Excluding Non-Drug Related) Treatment Group
DynaCirc CR®(isradipine)
(N=422)
Placebo
(N=186)
Edema 15.2% 2.2%
Headache 13.0% 12.4%
Dizziness 4.7% 2.7%
Fatigue 4.3% 2.2%
Abdominal Discomfort 2.8% 0.5%
Flushing 1.9% 0.5%
Constipation 1.7% 0.0%
Palpitations 1.2% 0.0%
Nausea 1.2% 1.6%
Abdominal Distention 1.2% 0.0%

The following adverse experiences were reported in 0.5%-1.0% or less of DynaCirc CR® (isradipine) or immediate-release DynaCirc® (isradipine) treated patients in hypertensive studies,or were noted in postmarketing experience with immediate-release DynaCirc® (isradipine) Capsules. More serious events are shown in italics. The relationship of these adverse experiences to isradipine administration is uncertain.

SKIN:Pruritus, urticaria, angioedema.

MUSCULOSKELETAL: Backache/pain, joint pain,neck pain/sore/stiff,legs ache/pain,cramps of legs/feet.

RESPIRATORY: Dyspnea, nasal congestion,cough.

CARDIOVASCULAR: Epistaxis,tachycardia,chest pain,shortness of breath,hypotension, syncope,atrial or ventricular fibrillation,myocardial infarction,heart failure.

GASTROINTESTINAL:Diarrhea,vomiting,appetite increased or decreased.

UROGENITAL: Pollakiuria,impotence,dysuria,nocturia.

CENTRAL NERVOUS: Drowsiness, insomnia, lethargy,nervousness, libido decrease/frigidity,impotence, depression, paresthesia (which includes numbness and tingling), transient ischemic attack,stroke.

AUTONOMIC: Dry mouth,hyperhidrosis,visual disturbance.

MISCELLANEOUS: Weight gain, throat discomfort, drug fever, leukopenia, elevated liver function tests.

No gastrointestinal bleeding has been reported in clinical trials with DynaCirc CR® (isradipine) Controlled Release Tablets.

In a long-term (one-year) DynaCirc CR® (isradipine) open-label, hypertension trial, the adverse events reported were generally the same as those seen in the short-term placebo-controlled studies. About 6% of DynaCirc CR® (isradipine) treated patients discontinued the long-term trial due to adverse reactions.

With immediate-release DynaCirc® (isradipine) Capsules, most of the adverse experiences were transient, mild, and related to vasodilatory effects.The following table shows the most common adverse events reported in U.S.clinical tri-als for immediate-release DynaCirc® (isradipine) Capsules, volunteered or elicited, and considered by the investigator to be at least possibly drug related.

Adverse Experience DynaCirc® (isradipine) Placebo
(N=297)
%
ActiveControls*
(N=414)
%
All Doses 2.5 mg b.i.d. 5 mg b.i.d. 10 mg b.i.d.††
Headache 13.7 12.6 10.7 22.0 14.1 9.4
Dizziness 7.3 8.0 5.3 3.4 4.4 8.2
Edema 7.2 3.5 8.7 8.5 3.0 2.9
Palpitations 4.0 1.0 4.7 5.1 1.4 1.5
Fatigue 3.9 2.5 2.0 8.5 0.3 6.3
Flushing 2.6 3.0 2.0 5.1 0.0 1.2
Chest Pain 2.4 2.5 2.7 1.7 2.4 2.9
Nausea 1.8 1.0 2.7 5.1 1.7 3.1
Dyspnea 1.8 0.5 2.7 3.4 1.0 2.2
Abdominal Discomfort 1.7 0.0 3.3 1.7 1.7 3.9
Tachycardia 1.5 1.0 1.3 3.4 0.3 0.5
Rash 1.5 1.5 2.0 1.7 0.3 0.7
Pollakiuria 1.5 2.0 1.3 3.4 0.0 <1.0
Weakness 1.2 0.0 0.7 0.0 0.0 1.2
Vomiting 1.1 1.0 1.3 0.0 0.3 0.2
Diarrhea 1.1 0.0 2.7 3.4 2.0 1.9
Initial dose of 2.5 mg b.i.d.followed by maintenance dose of 5.0 mg b.i.d.
††Initial dose of 2.5 mg b.i.d.followed by sequential titration to 5.0 mg b.i.d.,7.5 mg b.i.d.,and maintenance dose of 10.0 mg b.i.d.
*Propranolol,prazosin,hydrochlorothiazide,enalapril,captopril.

In open-label,long-term studies of up to two years in duration with immediate-release DynaCirc® (isradipine) Capsules, the adverse experiences reported were generally the same as those reported in the short-term controlled trials. The overall frequencies of these adverse events were slightly higher in the long-term than in the controlled studies, but in the controlled studies most adverse reactions were mild and transient.

Read the Dynacirc CR (isradipine) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Nitroglycerin: Immediate-release DynaCirc® (isradipine) has been safely coadministered with nitroglycerin.

Hydrochlorothiazide: A study in normal healthy volunteers has shown that concomitant administration of immediate-release DynaCirc® (isradipine) and hydrochlorothiazide does not result in altered pharmacokinetics of either drug. In a study in hypertensive patients, addition of isradipine to existing hydrochlorothiazide therapy did not result in any unexpected adverse effects, and isradipine had an additional antihypertensive effect.

Propranolol: In a single dose study in normal volunteers using immediate-release DynaCirc® (isradipine),co-administration of propranolol had a small effect on the rate but no effect on the extent of isradipine bioavailability. Significant increases in AUC (27%) and Cmax (58%) and decreases in tmax (23%) of propranolol were noted in this study.

Digoxin: The concomitant administration of immediate-release DynaCirc® (isradipine) and digoxin in a single-dose pharmacokinetic study did not affect renal, non-renal and total body clearance of digoxin.

Fentanyl Anesthesia: Severe hypotension has been reported during fentanyl anesthesia with concomitant use of a beta blocker and a calcium channel blocker. An increased volume of circulating fluids might be required if such an interaction were to occur.

Read the Dynacirc CR Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 12/30/2008
This monograph has been modified to include the generic and brand name in many instances.

A A A

Dynacirc CR - User Reviews

Dynacirc CR User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Dynacirc CR sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Hypertension

Get tips on handling your hypertension.